Leveraging record linkage for single-indication medications to boost recruitment in Psychiatric and Pharmaco- Genetics

全基因组关联研究（GWAS）表明，精神疾病是高度多基因的，通过增加参与者数量来提高这些分析的效力确实会导致新的治疗靶点和生物标志物的鉴定。我们寻求资金，通过使用处方记录招募那些只用于治疗这些疾病的处方药物的个人，来大大提高GWAS治疗精神分裂症和双相情感障碍的能力。

Genome-wide association studies (GWAS) have shown that psychiatric disorders are highly polygenic and that increasing the power of these analyses by increasing the number of participants does lead to the identification of new treatment targets and biomarkers. We seek funding to greatly boost the power of GWAS for Schizophrenia and Bipolar Disorder by using prescription records to recruit individuals who have been prescribed medications that are only used to treat these conditions.